Dutch Media Fined for Overly Positive Ozempic Coverage

Dutch media companies DPG Media and Mediahuis have been ordered to pay tens of thousands of euros in fines for publishing articles deemed too favorable toward the weight-loss medications Ozempic, Wegovy, and Mounjaro. The Dutch Health and Youth Care Inspectorate (IGJ) determined that the coverage constituted prohibited public advertising for prescription-only medications under the Dutch Medicines Act, according to VRT NWS.

The affected publications include De Volkskrant, AD, NRC, De Telegraaf, and lifestyle magazine Flair. Editors-in-chief have called the ruling an attack on press freedom, and DPG Media has announced it will appeal.

The Fines

DPG Media received two fines: €48,450 in April 2026 for articles in Flair and regional newspaper De Stentor, and €51,000 in August 2026 for articles in De Volkskrant and AD. Mediahuis, as owner of NRC and De Telegraaf, also received fines for articles in those newspapers, as reported by NOS.

The fines were imposed under Articles 84(2) and 85(a) of the Dutch Medicines Act, which prohibit public advertising for prescription-only medications and require advertising to be consistent with the product characteristics summary. The Amsterdam District Court ruled on April 10, 2026 that the articles in Flair and De Stentor constituted public advertising, a decision documented in the court ruling.

A Landmark Legal Interpretation

The court’s ruling is significant because it established that journalistic articles can constitute “public advertising” under the Medicines Act, even when the publisher has no commercial interest in the medication. The court applied a broad interpretation of “advertising” based on EU case law, focusing on the effect the publication has on readers rather than the intent of the publisher.

The court also found that the restriction on freedom of expression was justified under Article 10 of the European Convention on Human Rights, citing the protection of public health. The original fines were reduced by 80% by the Ministry of Health to account for freedom of expression and press freedom considerations.

The IGJ has been increasingly active in enforcing advertising rules, having imposed 20 fines for public advertising of medicines between 2023 and 2025. The inspectorate has also contributed to training for influencers about the rules and health risks around promoting medicines, as detailed in an IGJ weblog post.

Editors Respond: An Attack on Press Freedom

Pieter Klok, editor-in-chief of De Volkskrant, called the fines unprecedented. “We have never experienced this in the history of the newspaper, I think. It is unprecedented and incomprehensible,” he said. “This kind of big words you prefer to save for really serious matters, but this is an attack on press freedom.”

Corine de Vries, chair of the Dutch Association of Editors-in-Chief, expressed concern about a chilling effect on journalism. “Virtually all articles in which a benefit of the use of medicines and thus also weight-loss medication is described can receive a fine. It’s a kind of lottery,” she told Skipr. “The fines are high. We have not stopped writing about this subject, but we have become more cautious. It leads to restraint and that is a shame, because this is a major medical and societal trend about which we should be able to write.”

Government Response

Dutch Health Minister Sophie Hermans declined to comment on the specific case, stating that the inspectorate’s decision falls within its authority and responsibility. Media Minister Letschert said she would wait for the court’s ruling on the appeals, as reported by NOS. Hermans has agreed to meet with the Association of Editors-in-Chief next week.

The Broader Ozempic Phenomenon

The fines come amid a global surge in demand for GLP-1 medications. In Belgium, the RIZIV health insurance reimbursed a record €122.2 million for diabetes medications like Ozempic and Mounjaro in 2025 - more than four times the amount in 2019, with over 128,750 patients receiving such medications, as VRT NWS reported.

Nathalie Dens, professor of Media and Ethics at the University of Antwerp, questioned whether the articles should be classified as advertising. “With advertising, we must always speak of a payment in some form. In this case, it seems to me that it is more about reporting,” she said. “But I stick to my position that this is not advertising.”

What’s Next

DPG Media has announced it will appeal the ruling. The fines for NRC and De Telegraaf are reportedly not yet final, with those papers still able to submit their views. The meeting between Minister Hermans and the Association of Editors-in-Chief, scheduled for next week, will be closely watched as a potential avenue for clarifying the boundaries between journalism and advertising in health coverage.

The case raises fundamental questions about how media can report on significant medical developments while navigating strict pharmaceutical advertising regulations - a tension that will likely shape health journalism in the Netherlands and beyond for years to come.